Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
This map shows the geographic impact of Jay Herson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Herson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Herson more than expected).
This network shows the impact of papers produced by Jay Herson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Herson. The network helps show where Jay Herson may publish in the future.
Co-authorship network of co-authors of Jay Herson
This figure shows the co-authorship network connecting the top 25 collaborators of Jay Herson.
A scholar is included among the top collaborators of Jay Herson based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Jay Herson. Jay Herson is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Herson, Jay. (2006). Innovation in pharmaceuticals: Speeding up the development of new cures. 40(1). 25–29.10 indexed citations
9.
Herson, Jay, et al.. (1993). Discussion: Jay Herson, data monitoring boards in the pharmaceutical industry. Statistics in Medicine. 12.2 indexed citations
10.
Rockhold, Frank W., Gregory G. Enas, Peter B. Meier, et al.. (1993). Discussion: Frank W Rockhold and G Enas, data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations: George W Williams et al, monitoring of clinical trials and interim analyses from a drug sponsor's point of view. Statistics in Medicine. 12. 493–495.1 indexed citations
11.
Herson, Jay, Frederick P. Ognibene, David A. Peura, & William Silen. (1992). The role of an independent data monitoring board in a clinical trial sponsored by a pharmaceutical firm. 6(4). 285–292.3 indexed citations
Herson, Jay, et al.. (1978). Prognosis after metastases in osteosarcoma.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 1(4). 315–20.7 indexed citations
Herson, Jay, et al.. (1975). Comprehensive family planning services to an urban black community. A three year experience.. PubMed. 67(1). 61–5.1 indexed citations
20.
Herson, Jay, et al.. (1975). A retrospective study of gonorrhea incidence in an urban family planning clinic. 1(4). 146–149.3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.